» Articles » PMID: 30763746

Efficacy and Safety of Gamma Knife Radiosurgery for Meningiomas in Patients with Neurofibromatosis Type 2: A Long-Term Follow-Up Single-Center Study

Overview
Journal World Neurosurg
Publisher Elsevier
Date 2019 Feb 15
PMID 30763746
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To explore the efficacy and safety of Gamma Knife radiosurgery (GKRS) for meningiomas in patients with neurofibromatosis type 2 (NF2).

Methods: A series of 35 consecutive patients with 99 meningiomas in our department were retrospectively included from January 2000 to December 2015. Clinical records, magnetic resonance images, and follow-up data were reviewed.

Results: A total of 35 patients (25 women and 10 men) with 99 NF2-associated meningiomas were identified. All patients initially received GKRS. The patients' median age at the time of GKRS was 40 years (range, 16-61 years). The median prescription dose at the tumor margin was 13 Gy (range, 12-15 Gy). The median follow-up time was 96 months (range, 25-224 months). Twenty-nine patients received GKRS only once, and 6 patients received it multiple times. Six patients (17.1%) had radiation-related complications 7.5 ± 2.4 months after GKRS. Local control rates at 1, 3, and 5 years were 100%, 97.1%, and 90.6%, respectively. Distant control rates at 1, 3, and 5 years were 88.5%, 55.9%, and 45.5%, respectively. Five patients died of concomitant neurologic symptoms. No malignant transformation was observed during the follow-up periods in all 35 patients.

Conclusions: GKRS represents an effective and safe management strategy with minimal invasion for patients with NF2-associated meningiomas. Our data showed a high local control rate of NF2-associated meningiomas by GKRS; however, the distant control rate is low, especially in young patients. For these patients, retreatment with GKRS may still be the advisable method.

Citing Articles

Gamma knife stereotactic radiosurgery for neurofibromatosis 2 (NF2)-associated meningiomas; a systematic review and meta-analysis.

Habibi M, Mirjani M, Ahmadvand M, Delbari P, Alasti O, Akbari Javar M Acta Neurochir (Wien). 2025; 167(1):35.

PMID: 39907804 PMC: 11799078. DOI: 10.1007/s00701-025-06436-4.


Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients.

Wang J, Landry A, Raleigh D, Sahm F, Walsh K, Goldbrunner R Neuro Oncol. 2024; 26(10):1742-1780.

PMID: 38695575 PMC: 11449035. DOI: 10.1093/neuonc/noae082.


The clinical, genetic, and immune landscape of meningioma in patients with NF2-schwannomatosis.

Gregory G, Islim A, Hannan C, Jones A, Hammerbeck-Ward C, Rutherford S Neurooncol Adv. 2023; 5(Suppl 1):i94-i104.

PMID: 37287576 PMC: 10243851. DOI: 10.1093/noajnl/vdac127.


Skull Base Meningiomas in Patients with Neurofibromatosis Type 2: An International Multicenter Study Evaluating Stereotactic Radiosurgery.

Ruiz-Garcia H, Trifiletti D, Mohammed N, Hung Y, Xu Z, Chytka T J Neurol Surg B Skull Base. 2022; 83(Suppl 2):e173-e180.

PMID: 35832959 PMC: 9272243. DOI: 10.1055/s-0041-1722937.


Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2 patients: a systematic review and meta-analysis.

Tosi U, Maayan O, An A, Tusa Lavieri M, Guadix S, DeRosa A J Neurooncol. 2022; 156(2):431-441.

PMID: 35040021 DOI: 10.1007/s11060-021-03910-8.